Claims for Patent: 11,385,238
✉ Email this page to a colleague
Summary for Patent: 11,385,238
| Title: | Methods of protein clips recovery |
| Abstract: | The disclosed methods are directed to detecting polypeptide fragments (“clips”) of parental polypeptides. Parental polypeptides and clips are optionally denatured and then fractionated using a matrix. After a first elution (high molecular weight fraction), an additional elution step retrieves a low molecular weight fraction containing clips. If the clips are an appropriate size for the targeted detection method, such as mass spectrometry, then analysis of this fraction proceeds separately from the high molecular weight fraction, or the clips fraction is mixed with the proteolyzed high molecular weight fraction before analysis. However, if the clips are too large for the intended analytical method(s), then the clips are also proteolyzed. The digested high molecular weight and low molecular weight fractions can be analyzed separately or combined. Analysis of combined samples favors clip quantitation because the clips are analyzed together with the remaining counterpart of the parental polypeptide. |
| Inventor(s): | Da REN, Izydor APOSTOL, Alexander Julian VEACH |
| Assignee: | Amgen Inc |
| Application Number: | US16/022,850 |
| Patent Claims: |
Details for Patent 11,385,238
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | December 22, 1994 | 11,385,238 | 2038-06-29 |
| Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | October 28, 1996 | 11,385,238 | 2038-06-29 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | 11,385,238 | 2038-06-29 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | February 19, 2002 | 11,385,238 | 2038-06-29 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | 11,385,238 | 2038-06-29 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | May 12, 1998 | 11,385,238 | 2038-06-29 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | January 02, 2003 | 11,385,238 | 2038-06-29 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch